Kennedy Capital Management, Inc. Protalix Bio Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.27 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
48Shares Held
3.5MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.58 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$718,1010.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$616,6990.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$549,7320.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$445,5000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $82.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...